|
|
|
|
| LEADER |
00000cam a2200000Mu 4500 |
| 001 |
EBSCO_on1041918857 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr |n|---||||| |
| 008 |
180623s2018 xx o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCQ
|d K6U
|d OCLCO
|d OCLCF
|d YDX
|d N$T
|d UKAHL
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 066 |
|
|
|c (S
|
| 019 |
|
|
|a 1040624054
|a 1264792542
|
| 020 |
|
|
|a 9781681085623
|
| 020 |
|
|
|a 1681085623
|
| 035 |
|
|
|a (OCoLC)1041918857
|z (OCoLC)1040624054
|z (OCoLC)1264792542
|
| 050 |
|
4 |
|a RM267
|
| 082 |
0 |
4 |
|a 616.9/0461
|2 23
|
| 049 |
|
|
|a UAMI
|
| 100 |
1 |
|
|a Atta-ur-Rehman.
|
| 245 |
1 |
0 |
|a Frontiers in Anti-Infective Drug Discovery.
|
| 260 |
|
|
|a Sharjah :
|b Bentham Science Publishers,
|c 2018.
|
| 300 |
|
|
|a 1 online resource (293 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Frontiers in Anti-Infective Drug Discovery Ser. ;
|v v. 7
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|6 880-01
|a Intro; CONTENTS; PREFACE; List of Contributors; The Role of the Microbiota in the Genesis of Gastrointestinal Cancers; Edda Russo and Amedeo Amedei*; 1. INTRODUCTION; 2. THE HUMAN MICROBIOTA; 3. THE GASTROINTESTINAL MICROBIOTA; 3.1. Composition and Activities; 3.2. Gastro-Intestinal Colonization by the Microbiota and Selection; 3.3. The Human Microbiome Project; 3.4. Gut Enterotypes; 4. THE ROLE OF MICROBIOTA IN TUMOR DEVELOPMENT; 4.1. Proposed Models for Microbiota-induced Carcinogenesis; 4.2. Antibacteria-Specific Immune Response and Cancer Promotion; 5. MICROBIOTA AND GI CANCERS.
|
| 505 |
8 |
|
|a 5.1. Gut Bacteria Dysbiosis Associated with GI Cancer5.2. Microbiota Involvement in Gastric and Esophageal Cancers, the Role of Helicobacter pylori; 5.3. Microbiota Involvement in Colorectal Cancer; 5.3.1. Specific Gut Bacteria and CRC; 5.3.2. Bacteria Metabolites and CRC; 5.4. Gallbladder Cancer; 5.5. Liver Cancer; 5.6. Pancreatic Cancer; 6. BENEFICIAL ACTIVITIES OF GUT MICROBIOTA; 6.1. Antitumorigenic Impact of Microbiota; 6.2. Manipulating the Microbiota for Cancer Therapy; 7. CONCLUSION; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES.
|
| 505 |
8 |
|
|a Towards Host Cell-Targeting Therapies to Treat Dengue Virus InfectionsCybele C. García1,2, Verónica M. Quintana1, Viviana Castilla1 and Elsa B. Damonte1,2,*; INTRODUCTION; INTERACTION WITH CELL RECEPTORS; ENDOCYTOSIS AND FUSION FOR UNCOATING; LIPID METABOLISM; PROTEIN TRANSLATION; UNFOLDED PROTEIN RESPONSE; UBIQUITIN PROTEASOME PATHWAY; NUCLEOTIDE METABOLISM; KINASES; Mitogen-activated Protein Kinases; ERK Pathway; JNK Pathway; p38 Pathway; Other Kinases; Src, Ab1 and Fyn Kinases; AP2-associated Protein Kinase 1 and Cyclin G-associated Kinase; Phosphatidylinositol 3 Kinase/Akt Pathway.
|
| 505 |
8 |
|
|a SCREENING STRATEGIES TO CHARACTERISE PLANT PRODUCTS WITH POTENTIAL RESISTANCE MODIFYING ACTIVITYASSESSMENT OF SYNERGISTIC INTERACTION BETWEEN ANTIBIOTIC AND A PHYTOCOMPOUND AGAINST RESISTANT BACTERIA; Fractional Inhibitory Concentration Index (FICI); Modulation Factor (MF); Isobologram; SEARCH FOR PLANT-DERIVED SECONDARY METABOLITES WITH PROSPECTIVE RESISTANCE MODIFYING ACTIVITY; Key Early Studies Pertaining to Discovery of RMAs from Plants; Recent Studies; PHYTOCHEMICALS AND RELEVANT BACTERIAL RESISTANCE MECHANISMS; Efflux Pump Inhibition; Alteration of Bacterial Cell Membrane Permeability.
|
| 500 |
|
|
|a Protein Synthesis Inhibition.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Anti-infective agents.
|
| 650 |
|
0 |
|a Communicable diseases.
|
| 650 |
|
2 |
|a Anti-Infective Agents
|
| 650 |
|
2 |
|a Communicable Diseases
|
| 650 |
|
6 |
|a Antiinfectieux.
|
| 650 |
|
6 |
|a Maladies infectieuses.
|
| 650 |
|
7 |
|a Anti-infective agents
|2 fast
|
| 650 |
|
7 |
|a Communicable diseases
|2 fast
|
| 700 |
1 |
|
|a Chaudhry, Iqbal.
|
| 776 |
0 |
8 |
|i Print version:
|a Atta-ur-Rehman.
|t Frontiers in Anti-Infective Drug Discovery: Volume 7.
|d Sharjah : Bentham Science Publishers, ©2018
|z 9781681085630
|
| 830 |
|
0 |
|a Frontiers in Anti-Infective Drug Discovery Ser.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1828652
|z Texto completo
|
| 880 |
8 |
|
|6 505-01/(S
|a PROTEIN PROCESSINGEndoplasmic Reticulum α-glucosidases; Furin; Endoplasmic Reticulum Associated Signal Peptidase; INNATE ANTIVIRAL RESPONSE; Interferon Activity; Cell-intrinsic Restriction Factors; CONCLUDING REMARKS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Synergistic Interaction Between Plant Products and Antibiotics Against Potential Pathogenic Bacteria; Banasri Hazra1,*, Sutapa Biswas Majee2, Subhalakshmi Ghosh1 and Dhruti Avlani2; INTRODUCTION; BACTERIAL RESISTANCE TOWARDS CLINICAL ANTIBIOTICS; Background; Mechanisms and Associated Factors.
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL5430376
|
| 938 |
|
|
|a Askews and Holts Library Services
|b ASKH
|n AH37581022
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 15535280
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1828652
|
| 994 |
|
|
|a 92
|b IZTAP
|
